Role of FDG PET/CT in Patients With Metastasis of Unknown Origin

NCT06055764 | Not Yet Recruiting

• 1 other identifier: PET/CT in MUO
• Study Type: observational
• Target: 73
• Locations: 0 countries
• Sites: N/A

Brief Summary

Evaluatation of the role of F18FDG-PET/CT in patients with metastases of unknown origin.

Conditions

Metastasis

Outcome Measures

Primary Outcomes (1)

• Role of FDG PET/CT in patients with metastasis of unknown origin. Role of FDG PET/CT in patients with metastasis of unknown origin.

  patients with metastasis of unknown origin will do PET/CT searching for primary and find if it will change management or not Procedure: All PET-CT studies will be done at the nuclear medicine unit in Assuit University Hospital. PET-CT images will be interpreted at a workstation equipped with fusion software that offers multi-planar reformatted images and enables display of the PET images, CT images, and fused PET/CT images.

  through study completion an average 2 years

Interventions

PET/CT DEVICE

Patient preparation: Patients will fast for 4 - 6 h before PET scanning to optimize the blood sugar level to 160mg/dl. F-18 FDG dose was 0.14 mCi/kg and injected via intravenous route. During the uptake phase of 18F-FDG patients will be rested in a quite warm room. Procedure: All PET-CT studies will be done at the nuclear medicine unit in Assuit University Hospital. PET-CT images will be interpreted at a workstation equipped with fusion software that offers multi-planar reformatted images and enables display of the PET images, CT images, and fused PET/CT images.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This study will recruit patients with suspected or proven MUO referred to the nuclear medicine unit to detect primary site.

You may qualify if:

• Patients with age more than 18 years presented with either pathologically proved metastases of unknown primary or
• Patients with clinico-radiological suspicious of having metastases.

You may not qualify if:

• Age below 18 years,
• patients with pathologically proved primary tumor,
• Patients suffering from advanced disease and in-cooperative patients.
• Pregnant and lactating women.
• Patients who had motion artifacts, or those who can't stay stable or calm during acquisition.

Sponsors & Collaborators

• Assiut University: lead

Related Publications (2)

• Park JS, Yim JJ, Kang WJ, Chung JK, Yoo CG, Kim YW, Han SK, Shim YS, Lee SM. Detection of primary sites in unknown primary tumors using FDG-PET or FDG-PET/CT. BMC Res Notes. 2011 Mar 9;4:56. doi: 10.1186/1756-0500-4-56.

  PMID: 21385465 BACKGROUND

• Kwee TC, Kwee RM. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol. 2009 Mar;19(3):731-44. doi: 10.1007/s00330-008-1194-4. Epub 2008 Oct 17.

  PMID: 18925401 BACKGROUND

MeSH Terms

Conditions

Neoplasm Metastasis

Interventions

Positron Emission Tomography Computed Tomography

Condition Hierarchy (Ancestors)

Neoplastic Processes; Neoplasms; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Positron-Emission Tomography; Tomography, Emission-Computed; Image Interpretation, Computer-Assisted; Diagnostic Imaging; Diagnostic Techniques and Procedures; Diagnosis; Tomography, X-Ray Computed; Multimodal Imaging; Radiographic Image Enhancement; Image Enhancement; Photography; Radiography; Tomography, X-Ray; Radionuclide Imaging; Tomography; Diagnostic Techniques, Radioisotope

Study Officials

• Esraa Mamdouh

  Assiut University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Esraa Mamdouh

CONTACT

+20112322029; esraamamdouh22222@gmail.com

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Demonstrator of nuclear medicine Assiut university

Study Record Dates

• First Submitted: September 12, 2023
• First Posted: September 28, 2023
• Study Start: October 1, 2023
• Primary Completion (Estimated): September 1, 2026
• Study Completion (Estimated): December 1, 2026
• Last Updated: September 28, 2023

Record last verified: 2023-09